<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>NIH的顶级疫苗生产商希望Warp Speed成为新常态 The NIH’s top vaccine maker wants Warp Speed to be the new normal</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">The NIH’s top vaccine maker wants Warp Speed to be the new normal<br/>NIH的顶级疫苗生产商希望Warp Speed成为新常态 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-12-05 19:21:27</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/12/8aaf1afed3bbb6d1ecf00ac74991a1fa.jpg"><img src="http://img2.diglog.com/img/2020/12/8aaf1afed3bbb6d1ecf00ac74991a1fa.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>If the first vaccines against COVID-19 really do start coming online in a couple of weeks, that’ll be a blazingly fast scientific achievement—from new virus to new vaccine in just about 12 months, faster than ever before, and using a  new vaccine technology, too. Amazing! And also only sort of true, because the path of the two vaccines likeliest to become available first, one from the pharmaceutical companies Pfizer and BioNTech and one from Moderna, began long before people started getting sick in Wuhan in December 2019.</p><p>如果首批针对COVID-19的疫苗真的在几周内开始上线，那将是一项非凡的科学成就-从新病毒到新疫苗仅需约12个月，比以往任何时候都快，并且使用了新的疫苗技术。惊人！而且也只有一种事实，因为这两种疫苗最有可能首先获得使用，一种是来自辉瑞和BioNTech制药公司的一种，另一种是来自Moderna的疫苗，早在人们于2019年12月在武汉生病之前就开始了。</p><p> Like all scientific discoveries, that path has  many trailheads. One of them is the lab of John Mascola, director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases. He didn’t come up with the idea of using genetic material to make vaccines, but he and collaborators around the US spent years trying to direct those efforts against coronaviruses, the family that includes SARS-CoV-2, the cause of COVID-19. Most vaccines against the disease clue the immune system into seeing a specific protein on the surface of the virus; it was Mascola’s VRC that brought the mRNA for that “spike protein” to Moderna.</p><p> 像所有科学发现一样，这条道路也有许多开拓性的途径。其中之一是美国过敏和传染病研究所疫苗研究中心主任约翰·马斯科拉（John Mascola）的实验室。他没有提出使用遗传材料制造疫苗的想法，但他和美国各地的合作者花费了数年的时间试图指导那些针对冠状病毒的研究，冠状病毒是包括SARS-CoV-2的家族，这是COVID-19的病因。大多数针对这种疾病的疫苗会提示免疫系统在病毒表面看到特定的蛋白质。是Mascola的VRC将该“钉蛋白”的mRNA引入了Moderna。</p><p> Mascola and his colleagues correctly foresaw what was coming and figured out how to get ready for it. And as an adviser to Operation Warp Speed, the US government’s vaccine-funding program, Mascola has been one of the voices helping to determine whether the new vaccines work, and how to get them to people. In this conversation, edited for length and clarity, WIRED talks with Mascola about the path that brought these vaccines to the cusp of distribution, what their warp-speed progress has taught people about COVID-19 and vaccinology, and what science knows (and doesn’t know) about what’ll happen next.</p><p> Mascola和他的同事正确地预见了即将发生的事情，并弄清楚了如何做好准备。作为美国政府疫苗资助计划“扭曲行动”的顾问，马斯科拉一直是帮助确定新疫苗是否有效以及如何将其推广给人们的声音之一。在为长度和清晰度进行编辑的对话中，WIRED与Mascola进行了交谈，讨论了将这些疫苗推向销售热潮的途径，其飞速发展已经使人们了解了COVID-19和疫苗学，科学知道了什么（并且没有（不知道）接下来会发生什么。</p><p> WIRED:  You  advocated for developing new vaccines and new ways to make them—and basing them on mRNA—long before COVID-19 was a thing. These last few weeks must feel like something of a vindication.</p><p> 连线：您提倡开发新疫苗和新方法，并以mRNA为基础-在COVID-19成为现实之前就已经存在。这最后几个星期一定感觉是一种辩护。</p><p> John Mascola: I would say it’s gratifying for sure, more than a vindication. We had a belief that these new technologies, DNA and RNA vaccines, could play a major role in vaccinology and in responding to a pandemic. So it’s really nice to see that come true.</p><p> 约翰·马斯科拉（John Mascola）：我要说的肯定是令人欣慰的，不仅仅是辩护。我们相信，DNA和RNA疫苗这些新技术可以在疫苗学和应对大流行中发挥重要作用。因此，很高兴看到这一梦想成真。</p><p> How did the VRC’s work on mRNA and the spike protein end up being developed by Moderna, a relatively small and inexperienced pharmaceutical company?</p><p> VRC在mRNA和刺突蛋白上的工作成果是如何由相对较小且经验不足的制药公司Moderna开发的？</p><p> Our partnership started probably with working on the disease Zika in 2017, or maybe even before. We looked at a number of companies who were doing RNA vaccines, and we came to have a good working relationship with Moderna because we had a strong mutual interest in infectious disease vaccines. So it was a very good fit, and we were pretty convinced that they had a very robust, strong scientific capability to make RNA vaccines. Moderna was interested in working on Zika, they had some funding from Barda—the Biomedical Advanced Research and Development Authority—and they wanted a scientific partnership to work on the design of the vaccine. So we had a collaboration going back to Zika, and then after that passed, we talked to them about other areas of mutual interest. We proposed that coronaviruses would be a fruitful area for both of us.</p><p> 我们的合作伙伴关系可能始于2017年甚至更早的Zika病研究工作。我们考察了许多正在生产RNA疫苗的公司，我们之所以与Moderna建立了良好的合作关系，是因为我们对传染病疫苗有着强烈的共同兴趣。因此非常合适，我们非常确信他们具有制造RNA疫苗的强大，强大的科学能力。 Moderna对研究Zika感兴趣，他们得到了生物医学高级研究与开发管理局Barda的一些资助，并且他们希望建立科学的合作伙伴关系来设计疫苗。因此，我们与Zika进行了一次合作，然后通过了合作，然后与他们讨论了共同感兴趣的其他领域。我们认为，冠状病毒对我们俩都是一个富有成果的领域。 </p><p>    That was a really good—well, not “guess,” I suppose, but a good hypothesis, right? That a coronavirus was going to be a problem?</p><p>那真是一个好东西，好吧，我想这不是“猜测”，而是一个很好的假设，对吧？那冠状病毒会是个问题吗？</p><p> We were hedging our bets. No one knew what the next outbreak would be. It could have been a variant of influenza; it could have been one of a number of pathogens. But yeah, the short answer is, if you look at a list of outbreaks over the last 20 years, if two of the viruses on the list are in the coronavirus family, then you shouldn’t be shocked that it comes up again. SARS was 2002. MERS was 2012. In pandemic history, that’s a pretty short timeframe.</p><p> 我们在押注我们的赌注。没有人知道下一次爆发会是什么。它可能是流感的一种变体；它可能是许多病原体之一。但是，是的，简短的答案是，如果您查看过去20年的暴发清单，并且该清单中的两种病毒都属于冠状病毒家族，那么您再次出现它就不会感到震惊。 SARS是2002年。MERS是2012年。在大流行历史中，这是一个很短的时间范围。</p><p> So we did some work with Moderna on designing MERS vaccines—all early, preclinical—so we were able to test how our mRNA worked, and we could test some designs on what the RNA should teach the body to make an immune response against. We had a lot of groundwork already laid when we found out the new virus was a coronavirus.</p><p> 因此，我们与Moderna一起在早期临床前设计了MERS疫苗，因此我们能够测试我们的mRNA的工作方式，并且可以针对RNA应当教给人体的免疫反应进行一些设计测试。当我们发现新病毒是冠状病毒时，我们已经奠定了很多基础。</p><p> That groundwork focused on the spike protein, the protein on the surface of coronaviruses that they use to infect other cells. Did you worry that the spike protein work on MERS wouldn’t translate to the COVID-19 virus, to SARS-CoV-2?</p><p> 这项工作的重点是刺突蛋白，即冠状病毒表面上用来感染其他细胞的蛋白。您是否担心在MERS上起作用的刺突蛋白不会转化为COVID-19病毒或SARS-CoV-2？</p><p> For both the original SARS and for MERS, we were able to manipulate the spike protein to make it into a good vaccine. That required understanding how the spike looks atomically—what its actual structure is—and then making some changes to hold it into the right configuration, so the immune system sees the right thing. That worked for both SARS and for MERS, so we were confident, but not sure, that if another coronavirus came we could apply the same structure-based stabilizing mutations. That was work led by Barney Graham at our center. We were able to look just at the genetic sequence of the virus and the genetic sequence of the spike protein, and then transfer what we did from the original SARS into this new SARS-CoV-2. Those mutations worked right out of the box. So we were way ahead of the game.</p><p> 对于原始的SARS和MERS，我们都能够操纵刺突蛋白使其成为优质疫苗。这需要了解尖峰的原子外观（其实际结构是什么），然后进行一些更改以使其保持正确的构型，以便免疫系统看到正确的事物。这对SARS和MERS均有效，因此我们有信心但不确定，如果出现另一种冠状病毒，我们可以应用相同的基于结构的稳定突变。那是我们中心的Barney Graham领导的工作。我们能够仅查看病毒的遗传序列和刺突蛋白的遗传序列，然后将我们从原始SARS所做的工作转移到新的SARS-CoV-2中。这些突变立即可用。因此，我们领先于游戏。</p><p>  We actually were fortunate, scientifically, that we understood coronaviruses well. And it turned out the very first design the scientific community made for the spike protein worked. But let’s play it out. Let’s say we made a design, and it didn’t work out too well, and we had to go back and do a second-generation design. Now we’ve lost three or four months. Think of where the world would be. For Zika, our center, working with Moderna, made two designs of the analogous protein—not the spike protein, but a surface protein on the virus. The first one we took to the clinic didn’t work too well, didn’t induce a very good immune response. The second one did. That’s common in science.</p><p>  从科学上来说，实际上我们很幸运，我们对冠状病毒了解得很好。原来，科学界为刺突蛋白所做的第一个设计就是有效的。但是，让我们开始吧。假设我们做了一个设计，但效果不佳，我们不得不回去做第二代设计。现在我们已经失去了三四个月。想想世界会在哪里。对于Zika，我们的中心与Moderna一起设计了两种类似蛋白的设计-不是刺突蛋白，而是病毒表面的蛋白。我们带到诊所的第一个效果不佳，没有引起很好的免疫反应。第二个做到了。这在科学界很普遍。</p><p> A more wonkish question. Why have an Operation Warp Speed at all? Its mission seems like what your VRC is already supposed to do.</p><p> 一个更古怪的问题。为什么根本要有“操作扭曲速度”？它的任务似乎就像您的VRC应该执行的那样。 </p><p> It’s an important distinction. I argued for standing up Operation Warp Speed. Because I’m director of the vaccine center, I know what we can do, but I also know what the limitations are. The National Institutes of Health can develop a vaccine and bring it to early phase testing, but NIH doesn’t commercialize a vaccine or produce it in mass scale. That takes a private sector partner. Also NIH doesn’t fund the advanced development of products the way Barda does. Many of us who have been in government a long time and seen epidemics before realized that when you have such a serious epidemic, the response should be integrated across government.</p><p>这是一个重要的区别。我主张站起“扭曲速度”行动。因为我是疫苗中心的负责人，所以我知道我们能做什么，但我也知道局限性。美国国立卫生研究院可以研发疫苗并将其用于早期阶段的测试，但NIH并未将其商业化或大规模生产。这需要一个私营部门的合作伙伴。此外，NIH并没有像Barda那样资助产品的高级开发。我们中的许多人已经在政府工作了很长时间，并且在没有流行之前就意识到，当您患有如此严重的流行病时，应对措施应该在整个政府中统一起来。</p><p>     The recommendation to bring in an outside adviser also came from a number of us in government. My experience in the VRC working with companies is, if you want to partner with a company, you need to understand their incentives. I’m a government researcher; I know what my incentives are. What’s the incentive for Moderna to come work with us? Pfizer said they wouldn’t, that they’d do it on their own. What if everyone said that? When you bring someone in from Big Pharma to run the program, you gain their perspective. That’s value added to the public.</p><p>     引入外部顾问的建议也来自我们政府中的一些人。我在VRC与公司​​合作中的经验是，如果您想与公司合作，则需要了解他们的动机。我是政府研究员；我知道我的动机是什么。 Moderna与我们一起工作的动机是什么？辉瑞公司表示不会，他们会自己做。如果每个人都这么说怎么办？当您从Big Pharma引进某人来运行该程序时，您会得到他们的见解。这是向公众增加的价值。</p><p> You cowrote an  article in the journal  Science—with Anthony Fauci, the head of the National Institute for Allergy and Infectious Diseases—that laid out a rationale for the simultaneous testing of lots of  different kinds of vaccines against COVID-19, which happened. But you also said that the ways those trials are conducted and the kind of data they collect should be harmonized. To my eye, that didn’t happen. The trials assess different  clinical endpoints, and no one is testing vaccines head to head. The drug companies are running their own trials rather than having independent researchers conduct them. Are you confident in that setup?</p><p> 您在《科学》杂志上与国家过敏和传染病研究所所长Anthony Fauci一起撰写了一篇文章，该文章提出了同时测试针对COVID-19的多种不同疫苗的同时测试的原理。但是您还说，应该统一进行这些试验的方式和收集的数据类型。在我看来，这没有发生。该试验评估了不同的临床终点，没有人面对面地测试疫苗。制药公司正在进行自己的试验，而不是由独立的研究人员进行试验。您对这种设置有信心吗？</p><p> There was an enormous amount of discussion about that point. OK, so as you know, the funding entity is Barda. Generally speaking, when Barda funds in more traditional ways, they say, “We would like you to develop a coronavirus vaccine, and so here’s some contractual money, and you have to report to us and you have to meet milestones.” So that would be, every company does its own thing. Nothing would be coordinated. Of course, nobody espoused that.</p><p> 关于这一点进行了大量讨论。好的，正如您所知，资金实体是Barda。一般来说，当Barda用更传统的方式资助时，他们会说：“我们希望您开发冠状病毒疫苗，所以这是一笔合同费用，您必须向我们报告，并且必须达到里程碑。”因此，每个公司都会做自己的事。什么都不会协调。当然，没有人支持。</p><p> And on the other side, you could have the government control everything and say, “It’s going to be one protocol, and you all supply your vaccine.” That was discussed. It’s called a master protocol, and it is a good idea for some situations. But with COVID-19, number one, the vaccines were coming in at different times. So you can never really test them head to head. And your control group, which is pivotal, changes, because the epidemic changes. So your control group really has to be contemporaneous with your vaccine. Two, the vaccine trials are enormously large, as you know—30,000, 40,000, 60,000 people. Multiplied by five, that’s larger really than any one entity can coordinate. And the third reason is, the data that are required to submit to the Food and Drug Administration to get a license have to be submitted by a company, to commercialize the vaccine. So for speed and efficiency, it’s better to have a company recognized by the FDA as the responsible entity for the product in the trial.</p><p> 另一方面，您可以让政府控制一切，然后说：“这将是一个协议，并且您都可以提供疫苗。”讨论过了。它称为主协议，在某些情况下是个好主意。但是，随着COVID-19（排名第一）的出现，疫苗在不同的时期问世。因此，您永远无法真正对它们进行正面测试。至关重要的对照组也会改变，因为该流行病发生了变化。因此，您的对照组确实必须与您的疫苗同时使用。第二，您知道疫苗的试验规模非常大，分别有30,000、40,000、60,000人。乘以5，实际上比任何一个实体都能协调的都要大。第三个原因是，要使疫苗商业化，必须向公司提交要获得食品和药物管理局许可的数据。因此，为了提高速度和效率，最好让FDA认可一家公司作为该产品在试验中的负责人。</p><p> But Operation Warp Speed imposes a stringent set of requirements on how they conduct the trial. So it’s not a master protocol, but the protocols are what we call harmonized. They’re not exactly the same, but if you take a step back and look, they all had a very similar design. The protocols and the primary and secondary endpoints were approved by Operation Warp Speed, and each sponsor had to work with the NIH to co-conduct the study. And the oversight group, the Data Safety Monitoring Board, was established by NIH and had to be the same for each of the trials that was funded by Operation Warp Speed. So there were those harmonizing elements that ended up being the way we proceeded.</p><p> 但是“经纱速度操作”对他们如何进行审判提出了严格的要求。因此，它不是主协议，而是所谓的协调协议。它们并不完全相同，但是如果您退后一步看看，它们的设计都非常相似。该方案以及主要终点和次要终点均获得了经编速度行动的批准，每个赞助商都必须与NIH合作开展这项研究。由美国国立卫生研究院（NIH）成立的监督小组，即数据安全监视委员会，对于由“经纱速度行动”（Operation Warp Speed）资助的每项试验必须保持相同。因此，这些协调元素最终成为我们前进的方式。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2020/12/the-nihs-top-vaccine-maker-wants-warp-speed-to-be-the-new-normal/">https://arstechnica.com/science/2020/12/the-nihs-top-vaccine-maker-wants-warp-speed-to-be-the-new-normal/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/顶级/">#顶级</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/top/">#top</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>